Issue of Equity

Immediate release

3 march 2004

                                  SOPHEON PLC                                  

                          ('Sopheon' or 'the Group')                           

                                ISSUE OF EQUITY                                

Sopheon plc, the international provider of software and services that improve
the financial return from innovation and product development investments, has
today placed 2,000,000 ordinary shares to raise £620,000 (approximately before
expenses). In conjunction with continued market demand, the shares were placed
with GEM Global Yield Fund Limited under Sopheon's Equity Line arrangement,
underlining the funding potential of the instrument. The proceeds will be used
for the provision of working capital for the Company. Application has been made
for the new ordinary shares to be admitted to trading on AIM and dealings are
expected to commence on 9 March 2004.

Sopheon's Chairman, Barry Mence said:

'I am pleased that by placing this relatively small number of shares, we have
demonstrated the effectiveness of our equity line facility with GEM.
Notwithstanding the success of this exercise, I also wish to reassure
shareholders concerned by potential dilution, that we shall remain controlled
in our use of this instrument.'

For further information contact:

Barry Mence, Chairman   Sopheon plc               Tel : + 44 (0) 1483 685 735                       
Arif Karimjee, CFO                                                             
                                                                               
Adam Reynolds           Hansard Communications    Tel : + 44 (0) 207 245 1100                      
Ben Simons                                              + 44 (0) 771 309 0135     
                                                                               
Barbara Jansen          Citigate First Financial  Tel : + 31 (0) 205 754 010



About Sopheon

Sopheon (LSE: SPE) is an international provider of software and services that
help organizations improve the business impact of product development. The
Sopheon Accolade® product development system automates gate- or phase-based
product development processes and provides strategic decision support that
allows companies to improve innovation, cut product development spending waste
and shorten time to market. Sopheon's Monitor software operates as a 'reading
robot' that automatically reviews, filters, analyzes and pushes relevant
content to healthcare and engineering professionals to enable effective
compliance with protocols, standards and regulations. Sopheon is listed on the
AIM Market of the London Stock Exchange and on the Euronext in the Netherlands.
For more information, please visit www.sopheon.com.

                                      Sopheon preliminary results 2002 / page 2